Receipt of Notice That a Patent Infringement Complaint Was Filed Against a Biosimilar or Interchangeable Biosimilar Applicant, 7844 [2022-02799]
Download as PDF
7844
Federal Register / Vol. 87, No. 28 / Thursday, February 10, 2022 / Notices
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT:
Theresa Wells, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 5373,
Silver Spring, MD 20993–0002, 703–
380–3900.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Development of Non-Opioid
Analgesics for Acute Pain.’’ This draft
guidance is written in connection with
section 3001 of the SUPPORT Act to
provide information that will be useful
in the development of non-opioid
analgesics for the management of acute
pain and, thereby, spur the development
of such products.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on ‘‘Development of Non-Opioid
Analgesics for Acute Pain.’’ It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
jspears on DSK121TN23PROD with NOTICES1
II. Paperwork Reduction Act of 1995
18:18 Feb 09, 2022
Jkt 256001
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at either
https://www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: February 7, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–02858 Filed 2–9–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–4853]
Receipt of Notice That a Patent
Infringement Complaint Was Filed
Against a Biosimilar or
Interchangeable Biosimilar Applicant
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is publishing
notice that an applicant for a biologics
license application (BLA) for a
biosimilar or interchangeable biosimilar
product submitted under the Public
Health Service Act (PHS Act) (a
‘‘subsection (k) applicant’’) notified
FDA that an action for patent
infringement was filed in connection
SUMMARY:
While this guidance contains no
collection of information, it does refer to
previously approved FDA collections of
information. Therefore, clearance by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501–
3521) is not required for this guidance.
The previously approved collections of
VerDate Sep<11>2014
information are subject to review by
OMB under the PRA. The collections of
information in 21 CFR part 314 have
been approved under OMB control
number 0910–0001; the collections of
information in 21 CFR part 312 for
conducting clinical trials and collecting
data for such trials have been approved
under OMB control number 0910–0014;
the collections of information pertaining
to Electronic Records and Electronic
Signatures have been approved under
OMB control number 0910–0303; the
collections of information pertaining to
the Requirements on Content and
Format of Labeling for Human
Prescriptions for ‘‘opioid-sparing’’
claims have been approved under OMB
control number 0910–0572; and the
collections of information found in the
Guidance for Industry on Expedited
Programs for Serious Condition—Drugs
and Biologics for expedited pathways to
support the development program for
non-opioid analgesics have been
approved under OMB control number
0910–0765.
PO 00000
Frm 00047
Fmt 4703
Sfmt 9990
with the applicant’s BLA. Under the
PHS Act, within 30 days after the
subsection (k) applicant is served with
a complaint in an action for patent
infringement described under the PHS
Act, the subsection (k) applicant shall
provide the Secretary of HHS with
notice and copy of such complaint. FDA
is required to publish notice of the
complaint in the Federal Register.
FOR FURTHER INFORMATION CONTACT:
Sandra Benton, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 1132,
Silver Spring, MD 20993–0002, 301–
796–1042, Sandra.Benton@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Biologics Price Competition and
Innovation Act of 2009 (BPCI Act) was
enacted as part of the Patient Protection
and Affordable Care Act (Pub. L. 111–
148) on March 23, 2010. The BPCI Act
amended the PHS Act and created an
abbreviated licensure pathway for
biological products shown to be
biosimilar to, or interchangeable with,
an FDA-licensed biological reference
product. Section 351(k) of the PHS Act
(42 U.S.C. 262(k)) sets forth the
requirements for an application for a
proposed biosimilar product and an
application or a supplement for a
proposed interchangeable product.
Section 351(l) of the PHS Act (42
U.S.C. 262(l)) describes certain
procedures for exchanging patent
information and resolving patent
disputes between a subsection (k)
applicant and the holder of the BLA
reference product. If a subsection (k)
applicant is served with a complaint in
an action for a patent infringement
described in section 351(l)(6) of the PHS
Act, the subsection (k) applicant is
required to provide the Secretary with
notice and a copy of the complaint
within 30 days of service. FDA is
required to publish notice of a
complaint received under section
351(l)(6)(C) of the PHS Act in the
Federal Register.
FDA received notice of the following
complaint under section 351(l)(6)(C) of
the PHS Act: AbbVie Inc. and AbbVie
Biotechnology Ltd. v. Alvotech HF,
1:21–cv–02258 (N.D. Ill., filed April 27,
2021).
FDA has only a ministerial role in
publishing notice of a complaint
received under section 351(l)(6)(C) of
the PHS Act and does not perform a
substantive review of the complaint.
Dated: February 4, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–02799 Filed 2–9–22; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\10FEN1.SGM
10FEN1
Agencies
[Federal Register Volume 87, Number 28 (Thursday, February 10, 2022)]
[Notices]
[Page 7844]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02799]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-4853]
Receipt of Notice That a Patent Infringement Complaint Was Filed
Against a Biosimilar or Interchangeable Biosimilar Applicant
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is publishing notice
that an applicant for a biologics license application (BLA) for a
biosimilar or interchangeable biosimilar product submitted under the
Public Health Service Act (PHS Act) (a ``subsection (k) applicant'')
notified FDA that an action for patent infringement was filed in
connection with the applicant's BLA. Under the PHS Act, within 30 days
after the subsection (k) applicant is served with a complaint in an
action for patent infringement described under the PHS Act, the
subsection (k) applicant shall provide the Secretary of HHS with notice
and copy of such complaint. FDA is required to publish notice of the
complaint in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Sandra Benton, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 1132, Silver Spring, MD 20993-0002, 301-
796-1042, [email protected].
SUPPLEMENTARY INFORMATION: The Biologics Price Competition and
Innovation Act of 2009 (BPCI Act) was enacted as part of the Patient
Protection and Affordable Care Act (Pub. L. 111-148) on March 23, 2010.
The BPCI Act amended the PHS Act and created an abbreviated licensure
pathway for biological products shown to be biosimilar to, or
interchangeable with, an FDA-licensed biological reference product.
Section 351(k) of the PHS Act (42 U.S.C. 262(k)) sets forth the
requirements for an application for a proposed biosimilar product and
an application or a supplement for a proposed interchangeable product.
Section 351(l) of the PHS Act (42 U.S.C. 262(l)) describes certain
procedures for exchanging patent information and resolving patent
disputes between a subsection (k) applicant and the holder of the BLA
reference product. If a subsection (k) applicant is served with a
complaint in an action for a patent infringement described in section
351(l)(6) of the PHS Act, the subsection (k) applicant is required to
provide the Secretary with notice and a copy of the complaint within 30
days of service. FDA is required to publish notice of a complaint
received under section 351(l)(6)(C) of the PHS Act in the Federal
Register.
FDA received notice of the following complaint under section
351(l)(6)(C) of the PHS Act: AbbVie Inc. and AbbVie Biotechnology Ltd.
v. Alvotech HF, 1:21-cv-02258 (N.D. Ill., filed April 27, 2021).
FDA has only a ministerial role in publishing notice of a complaint
received under section 351(l)(6)(C) of the PHS Act and does not perform
a substantive review of the complaint.
Dated: February 4, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-02799 Filed 2-9-22; 8:45 am]
BILLING CODE 4164-01-P